Attention Investors: Note: The depositories (CDSL/NSDL), in coordination with SEBI, have upgraded their investor mobile applications to provide a consolidated view of investors’ holdings in securities markets. CDSL: MyEasiApp | NSDL: Speede App Beware of fraudulent Calls, SMS, Emails, WhatsApp & Telegram messages assuring high returns and / or enticing you to invest money in the name of Aditya Birla Money by installing fake App from spurious links. You can download our Elevate App only from Google Play Store or Apple App Store or login to Elevate Web portal. Click Here to know more.
Experience finance made simple on the new ABCD app!
Scan to Download the App
One stop solution for all stock market enthusiasts
Whatsapp us!! We are Available.
Send HI on 8828800038
For Broking services
Call Toll Free Number :
1800-270-7000
( Mon - Fri: 9AM - 11PM )
( Sat & Sun: 9AM - 09PM )
Call N Trade
Call :
1800-108-9999
( 9AM to 11:30PM /11:55PM )
Acquire & service self-trading online & offline clients. Archive large-scale business success with the entire product range offered by us.
Earn while you refer client. No need to set up your own infrastructure.
Join our referral program, earn rewards when friends and family open accounts & transact. Spread the word, multiply your earnings!
Join the Entrepreneurial Tribe!
Aditya Birla Money Limited
Symbol : DAICHI | BSE Code : 526821 | Sector : CHEMICALS
Market Cap (₹ Cr.)
Turnover (₹ Cr.)
10/09/2026 BSE -10.20(-2.90)Close Price: ₹ 342.00 Volume: 287.00
10/09/2026 BSE -7.00(-1.95)Close Price: ₹ 352.20 Volume: 1,630.00
10/09/2026 BSE -8.90(-2.42)Close Price: ₹ 359.20 Volume: 809.00
10/09/2026 BSE 5.90(1.63)Close Price: ₹ 368.10 Volume: 612.00
10/09/2026 BSE -3.70(-1.01)Close Price: ₹ 362.20 Volume: 293.00
No Data Available
Net profit of Dai-ichi Karkaria rose 14550.00% to Rs 2.93 crore in the quarter ended June 2026 as against Rs 0.02 crore during the previous quarter ended June 2025. Sales rose 46.62% to Rs 57.84 crore in the quarter ended June 2026 as against Rs 39.45 crore during the previous quarter ended June 2025.
Dai-ichi Karkaria consolidated net profit rises 14550.00% in the June 2026 quarter
Dai-ichi Karkaria to declare Quarterly Results
Dai-ichi Karkaria to conduct AGM
In Cr.
Dai-Ichi Karkaria Limited (DIK) was incorporated on 13 May 1960. The Company is engaged in manufacturing of Specialty Chemicals. The manufacturing activities of the Company are carried out from plants located at Dahej (Gujarat) and Kurkumbh (Maharashtra). The Company manufactures speciality chemicals has a tie-up with Matsumoto to manufacture spin finishes, which are used for imparting lubrication and anti-static properties to textile filaments and yarns. It has enhanced the production capacity from 750 tons per annum to 3000 tons per annum.Over the past year, the company has focused on developing application-led innovation, particularly in its priority segments. As part of this strategy, it has established an Application Development laboratory in the agriculture chemicals space, for strengthening customer-centric product development and commercialization.DIK had set up a unit to manufacture certain bulk drugs omeprazole, menadione and calcium pentothenate, the last two will be manufactured in India for the first time.The expansion cum Diversification plan for High Molecular Weight Flocculants Project at Kurkumbh has been completed. Company had joint venture with project consultant for effluent treatment plants for increasing business. Company Bulk Drugs & Fine Chemical Projects for patented molecule processes were developed and were scaled up to commercial level by March-99. Company plans to start development of three new products in the pilot facility which is being upgraded presently to meet strict cGMP condition. Company also negotiating with foreign customer for product specific tie-ups in future. Company Spin fishes continue to do well & POY DTY finish has been accepted in the market & company hopes to get orders from leading synthetic fibre manufacturers.During the year 1999-2000, the company's successfully introduced eight new products in therapeutic areas of cardiovascular, antihistaminics, analgesics, anxiolytic, antidepressant and anticons